SCHEMBL5126371

SCHEMBL5126371

COc1ccc(C(=O)Nc2cc(-c3c(-c4cccc(C)c4)nc4ccc(Cl)nn34)ccn2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 19/20 0.63
MAPK13 O15264 15/20 0.63
MAPK12 P53778 15/20 0.63
MAPK11 Q15759 15/20 0.63
IKBKB O14920 1/20 0.47
PRKD3 O94806 1/20 0.47
MAP4K4 O95819 1/20 0.47
EGFR P00533 1/20 0.47
MAPK1 P28482 1/20 0.47
FLT4 P35916 1/20 0.47
KDR P35968 1/20 0.47
FRK P42685 1/20 0.47
MAPK8 P45983 1/20 0.47
MAPK9 P45984 1/20 0.47
CSNK1A1 P48729 1/20 0.47
CSNK1D P48730 1/20 0.47
CSNK1E P49674 1/20 0.47
CSNK1G2 P78368 1/20 0.47
PTK6 Q13882 1/20 0.47
ERBB4 Q15303 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5118483 0.89 MAPK14 (0.62) MAPK14MAPK13MAPK12MAPK11IKBKB
SCHEMBL5118813 0.88 MAPK14 (0.82) MAPK14MAPK13MAPK12MAPK11
SCHEMBL5115520 0.87 MAPK14 (0.65) MAPK14MAPK13MAPK12MAPK11CSNK1D
SCHEMBL5126526 0.85 MAPK14 (0.60) MAPK14MAPK13MAPK12MAPK11
SCHEMBL5120290 0.82 MAPK14 (0.81) MAPK14MAPK13MAPK12MAPK11
SCHEMBL5121209 0.81 MAPK14 (0.86) MAPK14MAPK13MAPK12MAPK11
Hydrochloric Acid SCHEMBL5112542 0.81 MAPK14 (0.80) MAPK14MAPK13MAPK12MAPK11
SCHEMBL5119305 0.80 MAPK14 (0.90) MAPK14MAPK13MAPK12MAPK11
SCHEMBL14131929 0.79 MAPK14 (0.79) MAPK14MAPK13MAPK12MAPK11
Hydrochloric Acid SCHEMBL5126323 0.79 MAPK14 (0.88) MAPK14MAPK13MAPK12MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080167314-A1 Condensed Imidazole Compound And Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-10 US disclosed
US-20080167314-A1 Condensed Imidazole Compound And Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-10 US disclosed
US-20080167314-A1 Condensed Imidazole Compound And Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-10 US disclosed
EP-1832588-A1 CONDENSED IMIDAZOLE COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2007-09-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167314-A1 Condensed Imidazole Compound And Use Thereof MAPK13, MMP13, MAPK3 MAPK14 5/4885MAPK13 1/4885MAPK12 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.